Jump to content

Midkine

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Monkbot (talk | contribs) at 18:54, 1 September 2015 (→Further reading: Task 7c: repair/replace et al. in cs1 author/editor parameters;). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Error: no context parameter provided. Use {{other uses}} for "other uses" hatnotes. (help). Template:PBB

Midkine (MK or MDK) also known as neurite growth-promoting factor 2 (NEGF2) is a protein that in humans is encoded by the MDK gene.[1]

Midkine is a basic heparin-binding growth factor of low molecular weight, and forms a family with pleiotrophin (NEGF1, 46% homologous with MK). It is a nonglycosylated protein, composed of two domains held by disulfide bridges. It is a developmentally important retinoic acid-responsive gene product strongly induced during mid-gestation, hence the name midkine. Restricted mainly to certain tissues in the normal adult, it is strongly induced during oncogenesis, inflammation and tissue repair.

MK is pleiotropic, capable of exerting activities such as cell proliferation, cell migration, angiogenesis and fibrinolysis. A molecular complex containing receptor-type tyrosine phosphatase zeta (PTPζ), low density lipoprotein receptor-related protein (LRP1), anaplastic leukemia kinase (ALK) and syndecans is considered to be its receptor.[2]

Role in cancer

MK appears to enhance the angiogenic and proliferative activities of cancer cells.[3] The expression of MK (mRNA and protein expression) has been found to be elevated in multiple cancer types, such as neuroblastoma, glioblastoma, Wilms’ tumors, thyroid papillary carcinomas,[3] colorectal, liver, ovary, bladder, breast, lung, esophageal, stomach, and prostate cancers.[4] Serum MK in normal individuals is usually less than 0.5-0.6 ng/ml, whereas patients with these malignancies have much higher levels than this. In some cases, these elevated levels of MK also indicate a poorer prognosis of the disease, such as in neuroblastoma, gliablastoma, and bladder carcinomas.[5] In neuroblastoma, for example, the levels of MK are elevated about three times the level in Stage 4 of the cancer (one of the final stages) than they are in Stage 1.[5]

In neuroblastoma, MK has been found to be over expressed in the cancer cells that are resistant to chemotherapeutic drugs.[6][7] The resistance to chemotherapy seems to be reversible by administering chemo-resensitization drugs, such as verapamil,[8] which acts not via MK alteration, but by inhibiting the P-glycoprotein pump that exports cytotoxins out of cells.[9] Since chemotherapeutic drugs are cytotoxic, the drugs administered are also exported by this pump, rendering the chemotherapy ineffective.[9] It has been found that when the neuroblastoma cells that are resistant to chemotherapy are grown in co-culture with the wild type (WT), or chemotherapy-sensitive cells, the resistance to chemotherapy is conferred to the wild type cells, and thus no cell death or senescence occurs in either cell type,[6] despite the chemotherapeutic treatment. MK has been identified as one of the factors that “transfers” this chemoresistance from the resistant cells to the WT cells.[7]

MK is a secreted protein, and is therefore found in the microenvironment (media) of the resistant neuroblastoma cells.[7] Following co-culture experiments and the determination that MK was one of the factors that was conferring chemo-resistance to the wild, non-resistant cell type,[7] the gene for MK was transfected into WT cells to determine if MK was overexpressed in the WT cells themselves, would the cells become resistant to chemotherapy independent of resistant cell influence. The tests further confirmed that MK specifically increased chemotherapeutic resistance in the transfected WT-MK cells versus regular WT cells, confirming the specific chemoresistant properties of MK.[6]

In addition, the mechanism for such anti-apoptotic (anti-cell death) activity was studied, specifically using the chemotherapeutic Doxorubicin (Adriamycin) on osteosarcoma (Saos2) cells.[6] Doxorubicin works by putting rampant cancer cells into a senescent state. MK, in WT-MK transfected cells versus WT cells, seemed to activate PKB (Akt), mTOR, and Bad protein, while it inactivated caspase-3.[6] PKB, mTOR, and Bad are all elements associated with the cell cycle survival pathway, whereas caspase-3 is important in the apoptotic pathway (cell death).[6] This indicates that MK caused the cells to initiate the survival pathway (via PKB, mTOR, and Bad activation) and inhibit the senescent or apoptotic pathway (via inhibiting caspase-3)[6] encouraging the chemoresistance seen in resistant cells and in the co-culture experiments. The activation and inhibition of these particular factors clearly is maintaining the immortal quality inherent in cancer cells and specifically in the resistant cell types. Stat-3, however, which is another survival pathway factor, does not appear to have any change in activation between the wild type cells and the MK-transfected WT cells,[6] as was initially believed from a previous study.[7]

MK may potentially be indirectly targeted as a cancer treatment as a result of its cancerous proliferation properties.[10] Drugs by the name of anti-cancer aptamers have been created to inhibit to proteins involved in MK’s cancer cell “activation”. Specifically, the extra-cellular matrix (ECM) protein nucleolin has been targeted with an aptamer that would bind nucleolin and prevent MK from being transported into cancerous cell nuclei, preventing the protein from enhancing the cancerous properties of the cell.[10] Miyakawa et al. have successfully established the method to prepare the MDK specific RNA aptamers[11] by the use of the recombinant midkine[12] and pleiotrophin.[13]

Mdk is also a tumor antigen able to induce CD8 and CD4 T cell responses (Kerzerho and al. 2010 Journal of Immunology)

HIV infection

Midkine binds to cell-surface nucleolin as a low affinity receptor. This binding can inhibit HIV infection.[14]

Trivia

References

  1. ^ Kaname T, Kuwano A, Murano I, Uehara K, Muramatsu T, Kajii T (August 1993). "Midkine gene (MDK), a gene for prenatal differentiation and neuroregulation, maps to band 11p11.2 by fluorescence in situ hybridization". Genomics. 17 (2): 514–5. doi:10.1006/geno.1993.1359. PMID 8406506.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  2. ^ Muramatsu Takashi (1 September 2002). "Midkine and pleiotrophin: two related proteins involved in development, survival, inflammation and tumorigenesis". J. Biochem. (Tokyo). 132 (3): 359–71. doi:10.1093/oxfordjournals.jbchem.a003231. PMID 12204104.
  3. ^ a b Kato M, Maeta H, Kato S, Shinozawa T, Terada T (October 2000). "Immunohistochemical and in situ hybridization analyses of midkine expression in thyroid papillary carcinoma". Mod. Pathol. 13 (10): 1060–5. doi:10.1038/modpathol.3880195. PMID 11048798.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  4. ^ Ikematsu S, Yano A, Aridome K, Kikuchi M, Kumai H, Nagano H, Okamoto K, Oda M, Sakuma S, Aikou T, Muramatsu H, Kadomatsu K, Muramatsu T (September 2000). "Serum midkine levels are increased in patients with various types of carcinomas". Br. J. Cancer. 83 (6): 701–6. doi:10.1054/bjoc.2000.1339. PMC 2363529. PMID 10952771.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  5. ^ a b Ikematsu S, Nakagawara A, Nakamura Y, Sakuma S, Wakai K, Muramatsu T, Kadomatsu K (May 2003). "Correlation of elevated level of blood midkine with poor prognostic factors of human neuroblastomas". Br. J. Cancer. 88 (10): 1522–6. doi:10.1038/sj.bjc.6600938. PMC 2377118. PMID 12771916.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  6. ^ a b c d e f g h Mirkin BL, Clark S, Zheng X, Chu F, White BD, Greene M, Rebbaa A (July 2005). "Identification of midkine as a mediator for intercellular transfer of drug resistance". Oncogene. 24 (31): 4965–74. doi:10.1038/sj.onc.1208671. PMID 15897897.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  7. ^ a b c d e Rebbaa A, Chou PM, Mirkin BL (June 2001). "Factors secreted by human neuroblastoma mediated doxorubicin resistance by activating STAT3 and inhibiting apoptosis". Mol. Med. 7 (6): 393–400. PMC 1950050. PMID 11474132.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  8. ^ Lavie Y, Cao H, Volner A, Lucci A, Han TY, Geffen V, Giuliano AE, Cabot MC (January 1997). "Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells". J. Biol. Chem. 272 (3): 1682–7. doi:10.1074/jbc.272.3.1682. PMID 8999846.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
  9. ^ a b Yusa K, Tsuruo T (September 1989). "Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells". Cancer Res. 49 (18): 5002–6. PMID 2569930.
  10. ^ a b Ireson CR, Kelland LR (December 2006). "Discovery and development of anticancer aptamers". Mol. Cancer Ther. 5 (12): 2957–62. doi:10.1158/1535-7163.MCT-06-0172. PMID 17172400.
  11. ^ Miyakawa S, Fujiwara M, Nakamura Y, Matsui T, and Sakuma S. Aptamer against midkine and use thereof. United States Patent 8080649, 2011
  12. ^ Murasugi A, Tohma-Aiba Y (2003). "Production of native recombinant human midkine in the yeast, Pichia pastoris". Protein Expr. Purif. 27 (2): 244–52. doi:10.1016/S1046-5928(02)00587-9. PMID 12597883.
  13. ^ Murasugi A, Kido I, Kumai H, Asami Y (2003). "Efficient production of recombinant human pleio-trophin in yeast, Pichia pastoris". Biosci. Biotechnol. Biochem. 67 (10): 2288–90. doi:10.1271/bbb.67.2288. PMID 14586125.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  14. ^ Said EA, Krust B, Nisole S, Svab J, Briand JP, Hovanessian AG (October 2002). "The anti-HIV cytokine midkine binds the cell surface-expressed nucleolin as a low affinity receptor". J. Biol. Chem. 277 (40): 37492–502. doi:10.1074/jbc.M201194200. PMID 12147681.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)

Further reading

Template:PBB Further reading

Template:PBB Controls

Retrieved from "https://en.wikipedia.org/w/index.php?title=Midkine&oldid=678970823"